Thus, CD19-negative relapse may be related to irregular CD19 expression in TP53-disrupted B-cell lymphoma and driven by CAR19 T-cell surveillance9,33,34. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.